YOLFTbeta
Ilsung Pharm

Ilsung Pharm

003120 · KO · Healthcare / Drug Manufacturers - Specialty & Generic

20,800.00KRW-50.00 (-0.24%)

Price History

Full chart

Market Stats

Previous Close20,850.00
Open21,000.00
Day Range20,700.00 – 21,200.00
52-Week Range17,120.00 – 29,300.00
Volume9.12K
Market Cap157.92B
P/E (TTM)0.00
Forward P/E1.70
Dividend Yield5.56%
Beta-0.19
50-Day Avg20,939.00
200-Day Avg21,582.00

About

Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular system products. The company was formerly known as Ilsung Pharmaceuticals Co., Ltd. and changed its name to Ilsung Is Co., Ltd. in April 2024. Ilsung Is Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Seok-geun Yoon
  • Employees0
  • Headquarters84-gil 9, Wonhyo-ro, Seoul, South Korea, Korea
  • Websitehttps://www.ilsungis.com

Leadership

  • Mr. Seok-geun YoonChairman & CEO · b. 1956

Financials

Income Statement

Currency: KRW2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue62.81B62.83B61.75B67.46B67.04B61.65B48.41B40.60B42.09B61.25B78.05B69.02B64.29B
Growth (%)-+0.03%-1.73%+9.26%-0.62%-8.04%-21.48%-16.13%+3.67%+45.52%+27.44%-11.58%-6.85%
Cost of Revenue41.92B41.66B39.75B42.47B40.80B39.06B30.25B27.42B25.95B33.31B41.97B41.97B36.41B
Gross Profit20.89B21.17B22.00B24.99B26.24B22.59B18.17B13.18B16.14B27.94B36.09B27.05B27.88B
Gross Margin33.26%33.69%35.63%37.04%39.15%36.65%37.52%32.47%38.33%45.61%46.23%39.19%43.37%
Operating Expense19.52B18.74B19.41B22.54B23.65B20.34B19.42B15.13B17.93B26.64B61.33B30.29B34.04B
Operating Income1.37B2.43B2.59B2.45B2.59B2.26B-1.26B-1.95B-1.80B1.30B-25.25B-3.25B-6.16B
Operating Margin2.18%3.87%4.19%3.64%3.86%3.66%-2.60%-4.80%-4.27%2.12%-32.35%-4.70%-9.58%
EBITDA----7.81B7.60B12.27B7.49B1.56B141.08B-18.24B14.82B6.19B
EBITDA Margin----11.65%12.33%25.34%18.45%3.71%230.34%-23.36%21.47%9.62%
Net Income7.96B4.03B98.85B3.02B2.63B2.95B6.72B3.22B-1.37B105.24B-20.94B13.09B1.17B
Net Income Margin12.67%6.42%160.10%4.47%3.92%4.78%13.88%7.93%-3.25%171.83%-26.83%18.97%1.81%
R&D417.76M212.55M318.93M237.14M303.96M131.81M93.49M109.21M99.08M1.51B588.08M354.36M494.91M
R&D as % of Total Revenue0.67%0.34%0.52%0.35%0.45%0.21%0.19%0.27%0.24%2.47%0.75%0.51%0.77%
Interest Expense0000010.00K5.45M13.88M12.63M12.63M23.87M36.22M35.40M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.01%0.03%0.03%0.02%0.03%0.05%0.06%

Balance Sheet

Currency: KRW2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets372.66B378.37B367.03B338.50B347.46B347.26B369.52B371.22B371.38B494.42B419.19B396.88B403.01B
Total Liabilities49.92B49.69B48.69B18.40B24.64B22.93B24.03B23.75B25.47B48.85B36.44B11.75B16.67B
Total Equity322.74B328.68B318.34B320.10B322.83B324.34B345.49B347.48B345.91B445.57B382.75B385.13B386.34B
Cash7.11B6.07B7.49B19.87B29.52B1.39B37.28B36.22B50.84B272.92B160.09B110.24B120.28B

Cash Flow

Currency: KRW2000-12-312001-12-312002-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow---5.06B4.19B6.04B-31.01B10.16B15.09B4.39B1.56B5.70B-38.97B-41.47B-4.26B3.88B
Investing Cash Flow----213.07M-4.89B-4.19B44.27B502.89M-14.84B-22.03B-1.12B10.43B266.83B---
Financing Cash Flow----3.85B-335.94M-671.88M-1.01B-1.01B-1.01B14.73B-1.44B-1.48B-5.74B---
Capital Expenditure0001.13B945.31M2.85B2.77B1.85B1.21B1.24B4.82B10.93B62.01B7.73B12.09B2.18B
Free Cash Flow-------8.31B13.76B3.15B-3.26B-6.91B-101.46B-49.20B-16.34B1.71B
Dividends Paid---410.59M335.94M671.88M1.01B1.01B1.01B1.01B1.15B1.15B1.15B29.66B10.20B6.82B
FCF to OCF-------81.79%91.18%71.74%-209.34%-121.21%260.39%118.63%383.98%43.95%
Dividend Paid to FCF-------12.13%7.32%32.01%-35.29%-16.64%-1.13%-60.28%-62.40%399.61%

Earnings

Report DateSep 30, 2007Dec 31, 2007Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Nov 15, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------------------------------------------------------
EPS Actual408.40263.3596.20314.40431.43131.6065.0087.60789.70133.88540.703331.502134.521182.03419.141525.37943.18263.4252.12-91.20209.0489.12161.28141.04405.72161.3846.6414099.21164.84128.7816.28152.19288.5445.9765.27-8.54268.94111.32-16.5674.7055.20511.42-48.63481.9772.003.5984.39259.93-736.1620.0298.02439.8071.0813411.66442.87205.312115.93-172.87657.53-5825.42-97.81-61.891411.28669.60225.76-604.6450.04498.57220.2330.29
Surprise----------------------------------------------------------------------
Timing------------------------------Pre-market---------------------------------------

Key Statistics & Ratios

Market Cap157.92B
Enterprise Value-54.64B
Trailing P/E0.00
Forward P/E1.70
PEG Ratio0.00
Price / Sales2.42
Price / Book0.41
Revenue (TTM)65.22B
Gross Profit (TTM)29.05B
EBITDA-1.67B
Profit Margin8.50%
Operating Margin-9.15%
Return on Equity1.47%
Return on Assets-0.79%
Shares Outstanding7.16M
Shares Float2.53M
Beta-0.19
Dividend Yield5.56%
Dividend Rate1,200.00
Payout Ratio1.50%

Dividends

20251×
1200.00Dec 29, 2025
20241×
1000.00Dec 27, 2024
20231×
1500.00Dec 27, 2023
20221×
4000.00Dec 28, 2022
20211×
150.00Dec 29, 2021
20201×
150.00Dec 29, 2020
20191×
150.00Dec 27, 2019
20181×
150.00Dec 27, 2018
20171×
150.00Dec 27, 2017
20161×
150.00Dec 28, 2016
20151×
150.00Dec 29, 2015
20141×
100.00Dec 29, 2014
20131×
50.00Dec 27, 2013
20121×
60.00Dec 27, 2012
20111×
100.00Dec 28, 2011
20101×
100.00Dec 29, 2010
20091×
100.00Dec 29, 2009
20081×
100.00Dec 29, 2008
20071×
100.00Dec 27, 2007
20061×
100.00Dec 27, 2006
20051×
80.00Dec 28, 2005
20041×
80.00Dec 29, 2004
20031×
60.00Dec 29, 2003
20021×
100.00Dec 27, 2002

Stock Splits

  • Apr 17, 20235:1